Atea Pharmaceuticals
| Site | |
|---|---|
| Stage of funding: | Completed |
| Therapeutic group: | Infectious Diseases |
| Type: | Drug |
Description
Atea Pharmaceuticals, Inc. is an emerging biopharmaceutical company which is engaged in the acquisition, discovery and development of novel antiviral therapeutics for RNA-based viruses. The company is engaged in clinical programs for treatment of life-threatening viral infections: COVID-19 (lead program), Hepatitis C, Respiratory syncytial virus (RSV) and Dengue fever.
Portfolio companies news
-
Clearside Biomedical, Inc. (“Clearside”), (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be shared as a late-breaking oral presentation during the 2018 annual meeting of the American Society of Retina Specialists , July 20-25 in Vancouver, Canada .
-
11 July 2018
Clearside Biomedical Appoints Carol Hoang as Vice President, Medical Affairs
-
10 July 2018
Blood Test Predicts Treatment Response and Survival for Patients with Metastatic Prostate Cancer
-
21 June 2018
Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index